Jade Biosciences, Inc.
No SEC Form 4 filings for $JBIO in the last 30 days.
See all $JBIO insider activity →Jade Biosciences (JBIO) reported Q2 2026 net loss of $55.8M and cash, cash equivalents and investments of $461.2M as of June 30, 2026, saying it funds operations into Q4 2028. R&D was $50.1M and G&A $8.9M. The company advanced JADE101 to Phase 2/3 and updated progress on JADE201 and JADE301.
Jade Biosciences (NASDAQ: JBIO) reported net losses of $55.8M for Q2 2026 and $96.1M for the first half of 2026, versus $32.1M and $70.3M a year earlier. Cash and investments totaled $461.2M at June 30, 2026 after a June equity financing. The company advanced JADE101, JADE201, and JADE301.
Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d40629dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update • Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-
Over the past 7 days, alphai's AI scored 3 news stories mentioning JBIO (Jade Biosciences, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent JBIO coverage spans earnings, corporate actions and market movers.
The filing combines cash runway guidance into Q4 2028 with multiple clinical-program updates, which can re-rate near-term risk and financing expectations.
Stronger liquidity extends runway, but widening losses and higher R&D cash burn increase dilution and execution risk for JBIO.
The filing adds new clinical efficacy and durability signals for JADE101 plus updated pipeline timelines, which can re-rate risk for IgA nephropathy and related valuation.
Jade Biosciences reported that its Q2 net loss widened as costs increased, according to the company. The update highlights higher operating expenses affecting profitability. Investors may monitor the cost trajectory and future funding needs as the company reports ongoing quarterly results.
The 8-K discloses a new, milestone-based licensing obligation and royalty economics that can change near-term cash needs and longer-term revenue expectations.
alphai scores every news story that mentions JBIO with an AI model for sentiment and relevance, and aggregates insider trades from Jade Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jade Biosciences (JBIO) reported Q2 2026 net loss of $55.8M and cash, cash equivalents and investments of $461.2M as of June 30, 2026, saying it funds operations into Q4 2028. R&D was $50.1M and G&A $8.9M. The company advanced JADE101 to Phase 2/3 and updated progress on JADE201 and JADE301.
1 min readJade Biosciences (NASDAQ: JBIO) reported net losses of $55.8M for Q2 2026 and $96.1M for the first half of 2026, versus $32.1M and $70.3M a year earlier. Cash and investments totaled $461.2M at June 30, 2026 after a June equity financing. The company advanced JADE101, JADE201, and JADE301.
6 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d40629dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update • Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-
6 min readJade Biosciences reported that its Q2 net loss widened as costs increased, according to the company. The update highlights higher operating expenses affecting profitability. Investors may monitor the cost trajectory and future funding needs as the company reports ongoing quarterly results.
1 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K NASDAQ false 0001798749 0001798749 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
4 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001798749 0001798749 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju
3 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readJade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-3.3 4 d161530dex33.htm EX-3.3 EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF JADE BIOSCIENCES, INC. (a Nevada corporation) (effective as of June 9, 2026) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office . The registered office of Jade Biosciences, Inc., a Nevada co
2 min readJade Biosciences (Nasdaq: JBIO) said it closed its public offering of 11.5 million shares of common stock, including 1.5 million shares from the underwriters’ full option. Shares were sold at $15.00 each, raising $172.5 million in gross proceeds. Jade plans to use net proceeds for clinical trials, preclinical studies, manufacturing, and R&D, plus working capital and general corporate purposes.
2 min readU.S. stock futures were mixed Thursday after a lower close Wednesday: Nasdaq 100 and S&P 500 rose, while Dow gained. Treasury yields were 4.49% (10-year) and 4.07% (2-year). CME FedWatch showed a 96.2% chance the Fed holds rates in June. CrowdStrike jumped on a 4-for-1 split; PVH fell 20.54% on guidance. Lululemon was up ahead of earnings.
6 min read
